Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 325–336 of 411 articles
- Interpret the evidence
What a Rat Recognition Task Can Tell Us About Selank and Memory
Selank is a synthetic peptide based on tuftsin. An older animal study tested it in a rat model involving prolonged alcohol exposure and withdrawal. The investigators measured performance on an object recognition task and looked at a protein related to nerve cell activity.
Selank1 source (2019)
- Interpret the evidence
Why the FDA Entry on Selank Acetate Is a Safety Source Rather Than an Approval
Selank is a seven-amino-acid peptide studied in nervous system research. FDA's compounding materials discuss Selank acetate, a named form of the substance. They are useful for understanding the agency's stated uncertainties about that material.
Selank2 sources (2024, 2026)
- Explore study findings
Why two approval records describe different ingredients
Semaglutide is a modified peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This entry names both molecules together.
SEMA / IGF-1 LR33 sources (2023–2026)
- Explore study findings
What IGF-1 LR3 did in a lab-made skin model
Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered version of a growth-factor protein. A 2026 tissue-engineering study used IGF-1 LR3 to investigate how cells build a supporting matrix in reconstructed skin tissue.
SEMA / IGF-1 LR32 sources (2026)
- Check methods and identity
Why a kidney trial measured body water as well as lean mass
Semaglutide acts at the GLP-1 receptor. IGF-1 LR3 is an altered, extended version of the growth-factor protein IGF-1. The 2026 SMART analysis studied semaglutide alone versus placebo and asked whether changes in body composition were related to kidney measurements.
SEMA / IGF-1 LR32 sources (2023, 2026)
- Check methods and identity
What separate Alzheimer’s studies measured for these two molecules
Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings.
SEMA / IGF-1 LR33 sources (2024, 2026)
- Interpret the evidence
Why the bimagrumab and semaglutide trial belongs to its exact combination
Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered growth-factor protein. A 2026 randomized trial tested semaglutide with a different add-on, the investigational antibody bimagrumab.
SEMA / IGF-1 LR32 sources (1992, 2026)
- Check methods and identity
What binding-protein measurements tell us about semaglutide
Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment.
SEMA / IGF-1 LR32 sources (1992, 2025)
- Explore study findings
What the 2026 FDA Appraisal Found About Semax and Stroke
Semax is a synthetic seven-amino-acid peptide derived in part from a region of adrenocorticotropic hormone. It has been studied in relation to cerebral ischemia, a loss of adequate blood flow to brain tissue.
Semax2 sources (2018, 2026)
- Check methods and identity
What Semax Changed in Gene Measurements After Experimental Ischemia
Semax is a synthetic peptide based in part on a region of adrenocorticotropic hormone. Researchers have used it in animal studies to ask whether parts of the brain respond differently after temporary loss and restoration of blood flow.
Semax1 source (2024)
- Interpret the evidence
Why the 2026 Glaucoma Report Could Not Isolate Semax’s Contribution
Semax is a synthetic seven-amino-acid peptide. A 2026 glaucoma report included Semax in both of its groups after surgery. The study is useful for showing why a report can contain a peptide and report a favorable outcome without isolating the effect of that peptide.
Semax1 source (2026)
- Interpret the evidence
What a Retinal Detachment Follow Up Compared After Surgery
Semax is a synthetic peptide investigated in some neurological and eye studies. In a 2026 report on retinal detachment, two groups were followed after surgery, and both groups received care involving Semax.
Semax1 source (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
